Fernandino L. Vilson
Papers
1
Total Citations
23
H-Index
1
About
Dr. Fernandino L. Vilson is a leading urologic oncologist whose research focuses on optimizing treatment strategies for upper tract urothelial carcinomas (UTUC), particularly through the integration of systemic neoadjuvant and adjuvant intravesical chemotherapy. His most cited work, a 2021 analysis of US claims data, provides critical insights into perioperative outcomes and health care costs associated with these therapies in patients undergoing radical nephroureterectomy—whether minimally invasive or open. This study, with 23 citations, has shaped clinical decision-making by highlighting the economic and survival benefits of chemotherapy sequencing. Dr. Vilson’s contributions extend to evaluating disparities in care and refining surgical approaches to improve patient quality of life. His research is widely recognized for bridging evidence-based oncology with real-world practice, influencing guidelines on multimodal management of UTUC. A dedicated clinician-scholar, Dr. Vilson continues to advance the field through collaborative trials and health services research, making his work essential reading for urologists and oncologists striving to balance efficacy, cost, and patient-centered outcomes.
Research Focus
Key Achievements
Top Papers
- 1